Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
Incara Pharmaceuticals
Download detailed PDF Members: Incara Pharmaceuticals Corporation focuses on the protection and regeneration of tissue damaged by injury and disease. The company currently has programs in three areas: liver cell therapy and progenitor cell therapy as a treatment for liver failure; small molecule catalytic antioxidants as treatment for stroke and tissue damage; and deligioparin (formerly named OP2000), an ultra-low molecular weight heparin being developed with Elan Corporation for treatment of ulcerative colitis.
This page has been viewed 1004 times since April 2007, the link to the organisation's website has been followed 196 times Recent Search Terms used to find this page: Incara Pharmaceuticals | Incara Pharmaceuticals | ncara | incara | incara pharmaceuticals | Incara Pharmaceuticals Corporation focuses on the protection and regeneration of tissue damaged by injury and disease. | Incara Pharmaceuticals Inc. | incara pharmaceuticals | incara pharmaceuticals | incara | . This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Incara Pharmaceuticals | ||||||||||||||||||||||||||||||
|